phenindione
Trade name: hedulin
Small moleculeapproved
Phenindione is an anticoagulant which functions as a Vitamin K antagonist. The drug was discontinued in USA, but still in use worldwide. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01758640)
Timeline
1950s
- Jun 1, 1952
Hed Pharmaceuticals — First NDA Organization
- Jun 1, 1952
Hed Pharmaceuticals — NDA Organization
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
- Atrial Fibrillation · Phase 3
- Atrial Flutter · Phase 3
- Cerebral Intraventricular Hemorrhage · Phase 3
- Cerebrovascular Disorders · Phase 3
- Hematoma, Subdural · Phase 3
- Hemorrhage · Phase 3
- Intracranial Hemorrhage, Hypertensive · Phase 3
- Intracranial Hemorrhages · Phase 3
- Pregnancy Complications · Phase 3
- Subarachnoid Hemorrhage · Phase 3
Mechanism of action
VKORC1 inhibitor
Approval history
- approved—
Chemistry & pharmacology
Loading structure…
SMILES
O=C1C(C(=O)C2=CC=CC=C12)C3=CC=CC=C3- Mol. weight
- 222.2387 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPhenindione ↗
- NCATS5M7Y6274ZE ↗
- ChEMBLCHEMBL711 ↗
- ChEMBLCHEMBL2108222 ↗
Also known as
- 2-phenyl-1,3(2h)-indenedione
- 2-phenyl-1,3(2h)-indenedione
- 2-phenyl-1,3-diketohydrindene
- 2-phenyl-1,3-diketohydrindene
- 2-phenyl-1,3-indandione
- 2-phenyl-1,3-indandione
- athrombon
- danedion
- dindevan
- dindevan
- diophindane
- emandione
- fenhydren
- fenindiona
- fenindiona
- fenindione
- fenindione
- fenindione
- hedulin
- hedulin
- hedulin
- hemolidione
- indion
- phenhydren
- phenillin
- phenindion
- phenindion
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phenindione
- phénindione
- phénindione
- phenindionum
- phenindionum
- phenylindandione
- phenylindanedione
- phenylindanedione
- phenylindione
- pid
- pid
- theradione
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03153150 | Phase 3 | Jul 3, 2017 | NHS Lothian, University of Edinburgh |
| NCT01758640 | Phase 3 | Feb 1, 2010 | Ain Shams University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| NHS Lothian | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Edinburgh | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Hed Pharmaceuticals | For profit | NDA | Jun 1, 1952 |
| Sanofi-Aventis | For profit | NDA2 | — |